Recombinant Human Papillomavirus (HPV) Nonavalent Vaccine
The HPV nonavalent vaccine protects against infection with low-risk HPV types 6 and 11, which cause most genital warts, and against high-risk HPV types 16, 18, 31, 33, 45, 52, and 58, which cause several types of precancers and cancer.
Use in Cancer
The HPV nonavalent vaccine is used in individuals aged 9 to 45 years to prevent:
- Anal cancer.
- Cervical cancer.
- Head and neck cancer, including oropharyngeal cancer.¹
- Vaginal cancer.
- Vulvar cancer.
- Lesions that sometimes lead to anal, cervical, vaginal, or vulvar cancer.
- Genital warts.
¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that recombinant human papillomavirus (HPV) nonavalent vaccine provides a clinical benefit in these patients.
More About Recombinant Human Papillomavirus (HPV) Nonavalent Vaccine
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Recombinant Human Papillomavirus (HPV) Nonavalent Vaccine - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Recombinant Human Papillomavirus Nonavalent Vaccine - Check for trials from NCI's list of cancer clinical trials now accepting patients.